Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.
about
Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma modelMoving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.The interconnectedness of cancer cell signaling.Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells.The pharmacological bases of the antiangiogenic activity of paclitaxel.VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinomaCancer subclonal genetic architecture as a key to personalized medicine.Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies.Metronomics: towards personalized chemotherapy?A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.Emerging roles of regulatory T cells in tumour progression and metastasis.In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer-associated biological processes.Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.Limiting the development of anti-cancer drug resistance in a spatial model of micrometastasesPhase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing doCoadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs.Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients.Resistance to metronomic chemotherapy and ways to overcome it.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integrationTumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts.Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapyDose Response of MTLn3 Cells to Serial Dilutions of Arsenic Trioxide and Ionizing Radiation.A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy.Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.Is There an Opportunity for Current Chemotherapeutics to Up-regulate MIC-A/B Ligands?First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study.Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma.
P2860
Q33720164-736ADA2B-FC39-4E47-B855-44124F2CF953Q34173568-E12B71A8-B501-48D4-BF7F-2C731C1D9B05Q35116804-2C7DB332-E47B-47AB-B9FC-E91D7D0F4EC2Q35669733-494F4D95-AC1B-4881-9ADD-FCB85C04F929Q35966821-A078FBDB-FC31-4875-BF5A-FF4A9F79401FQ36352501-08962D77-9E4F-4179-81D0-EBA9AE75CC8EQ36678312-82D8115E-5571-4A11-A64C-90DCA59A60A6Q36927558-544F4C4B-4693-460A-873C-C3C0116430E9Q37111160-B379C045-B556-4115-8BAF-DB0D9EF0778FQ37236004-06C62F75-A907-435A-BA40-AD1E971BDDD3Q37448116-4C8DCEEF-9F90-4225-A328-03057601758CQ38092582-6115FEF7-E769-49FB-B29D-B8FDD046C7B9Q38218923-2D0FD592-5B6D-4E02-9DD6-EEC4BB729595Q38249998-5D592EC8-69B9-456A-B4B8-3AAAF46B5CF8Q38264092-22FB514D-C566-43D9-8D11-B5B5C539F7E7Q38480926-F46D7A38-D630-49E6-8AD9-CB26062A9104Q38489591-4E5E9A96-13E2-4179-B6E2-CA88F4600F8DQ38722809-42BFA08B-CF4E-420F-8581-574FFC3755D3Q38738084-13F89D65-4AB9-4E77-8324-4122926A7B72Q38947623-90EDD519-F017-4795-BDC5-64AB7E0E7619Q39358604-70418598-972F-43A4-A599-F4F6EDB2EA7CQ39455513-FB5EFE52-8B47-4961-8B91-84A6C94DE484Q40448516-FA6E6852-DA5D-46F3-9BA1-4473D0F598BCQ41879186-B94A858F-C95F-4018-89B4-70EB16D96B57Q41912972-69FD2882-D2EE-40C7-8109-6DD7E51F55D3Q42180889-15D27C71-6DA5-41F7-9B7E-A09AE9DC4282Q43242926-48216943-E8B7-47BD-8C64-C5F98CEE499DQ43246662-CF0E33FD-3AB6-4CD3-9046-A258F16790B7Q44084942-4EBF0B19-2839-44AF-B6E7-CEED6A7B0DA7Q47110491-89FD2EDC-B549-4A18-92CB-0187D1087C8EQ48686558-B1D57B3F-7A93-4614-A4D2-032C188E314CQ51328292-EA9165EA-0A21-439A-89F0-0C8F185D2852
P2860
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@ast
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@en
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@nl
type
label
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@ast
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@en
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@nl
prefLabel
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@ast
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@en
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@nl
P2093
P2860
P356
P1433
P1476
Tumors that acquire resistance ...... lerated dose cyclophosphamide.
@en
P2093
Andrew Kouri
Annabelle Chow
Giulio Francia
Robert S Kerbel
Urban Emmenegger
Yuval Shaked
P2860
P356
10.1593/NEO.101174
P577
2011-01-01T00:00:00Z